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Death, disease, and tobacco
Throughout history, humanity has been blighted by 
epidemics of communicable diseases that medical 
science and public policy have, to varying degrees, 
been able to control. Sanitation, immunisation, 
mosquito nets, and antimicrobial agents are examples 
of developments that have helped to generate 
substantial reductions in incidence of and mortality 
from cholera, dysentery, smallpox, measles, HIV, 
tuberculosis, and many other infectious diseases. 
Similar success is now urgently required to halt the 
global spread of non-communicable diseases that have 
dominated health in high-income countries for the 
past century, and are now emerging as major disease 
burdens in low-income and middle-income countries.1 
This is especially true of the epidemics of lung cancer, 
chronic obstructive pulmonary disease (COPD), 
cardiovascular disease, and other disorders that are 
caused by tobacco smoking.
A new report in The Lancet using data from the 
Global Burden of Disease Study adds quantitative 
detail to an already extensive international literature 
on the health impact of the global tobacco epidemic 
by providing comprehensive estimates of death and 
disability caused by smoking at the country level.2 The 
findings are sobering. In 2015, smoking caused more 
than one in ten deaths worldwide, killing more than 
6 million people with a global loss of nearly 150 million 
disability-adjusted life-years.2 Smoking prevalence and 
consequent morbidity and mortality are now falling in 
most (but not all) rich countries, but future mortality 
in low-income and middle-income countries is likely 
to be huge. Worldwide, one in four men, and a total of 
933 million people, are estimated to be current daily 
smokers,2 and 80% of these smokers live in low-income 
and middle-income countries.3 Half of these, or half a 
billion people alive today, can be expected to be killed 
prematurely by their smoking unless they quit.3 At 
present, smoking prevalence is still low in countries 
with a low socio-demographic index,2,4 but, on past 
experience in richer countries, it is only a matter of time 
before men and then women in all countries take up 
smoking, and in due course die from lung cancer, COPD, 
and other diseases caused by smoking, as has happened 
in the richer world.5 Even though the prevalence 
of smoking is decreasing in many low-income and 
middle-income countries, including many of those with 
the most smokers (eg, China and India), population 
growth means that the number of smokers, and hence 
the burden of harm from smoking, continues to rise.2,4
Responsibility for this global health disaster lies 
mainly with the transnational tobacco companies, 
which clearly hold the value of human life in very 
different regard to most of the rest of humanity. For 
example, the latest annual report from British American 
Tobacco (BAT),6 historically the most global of today’s 
five transnational companies,7 details with apparent 
pride their geographical diversity, strong earnings 
and market share growth, market leadership in more 
than 55 countries, and manufacturing facilities in 
42 of them.6 In 2016, BAT sold 665 billion cigarettes, 
making £5·2 billion in profit; and recorded rising 
profits across most of the world.6 Countering the heft 
and influence of commercial behemoths such as this 
demands human resources, governance, expertise, 
and financial backing that few rich countries have yet 
to fully establish, let alone those countries at the lower 
end of the development spectrum. The WHO Framework 
Convention Alliance provides detailed guidance to 
support implementation of a growing range of effective 
tobacco control policies, including taxation, advertising 
bans, smoke-free policies, and protection against 
the vested interests of the tobacco industry,8 but, in 
most parts of the world, translating this guidance into 
effective legislation has a long way to go.9 Like in many 
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rich countries, tobacco control legislation too often 
becomes mired in procedure and delayed or otherwise 
undermined by tobacco industry misrepresentation 
of science, fearmongering over tax revenue and illicit 
supply, corporate social responsibility activities, offers 
of help drafting tobacco laws, threatened or real legal 
action, and, in some countries, economic dependence 
on tobacco growing, and conflicts of interest.10–14
The persistence of smoking in the countries first 
affected by the tobacco epidemic2 reflects decades of 
failure first to recognise smoking as a health problem, 
and second to take decisive action to implement the 
policies currently promoted by the WHO Framework 
Convention on Tobacco Control, but articulated long 
ago in the Royal College of Physicians’ report of 1962.15 
Today, the smoking epidemic is being exported from 
the rich world to low-income and middle-income 
countries, slipping under the radar while apparently 
more immediate priorities occupy and absorb scarce 
available human and financial resources. The epidemic 
of tobacco deaths will progress inexorably throughout 
the world until and unless tobacco control is recognised 
as an immediate priority for development, investment, 
and research. Rich-world experience also teaches that 
where the tobacco industry leads and succeeds today, so 
the alcohol and food industries follow tomorrow.16
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